Comparative effectiveness and costs of generic and brand-name gabapentin and venlafaxine in patients with neuropathic pain or generalized anxiety disorder in Spain

Antoni Sicras-Mainar,1 Javier Rejas-Gutiérrez,2 Ruth Navarro-Artieda3 1Planning Directorate, Badalona Serveis Assistencials SA, Badalona, Barcelona, Spain; 2Department of Health Economics and Outcomes Research, Pfizer SLU, Alcobendas, Madrid, Spain; 3Medical Documentation, Hospital Germans Trias i P...

Full description

Saved in:

Bibliographic Details
Main Authors:	Sicras-Mainar A (Author), Rejas-Gutiérrez J (Author), Navarro-Artieda R (Author)
Format:	Book
Published:	Dove Medical Press, 2015-06-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Influencia de la sustitución de medicamentos de marca por genéricos en el cumplimiento terapéutico de la hipertensión arterial y la dislipidemia Influence of substitution of brand name for generic drugs on therapeutic compliance in hypertension and dyslipidemia
by: Antoni Sicras Mainar, et al.
Published: (2010)

North American cost analysis of brand name versus generic drugs for the treatment of glaucoma
by: Malvankar-Mehta MS, et al.
Published: (2019)

Severe Atopic Dermatitis In Spain: A Real-Life Observational Study
by: Sicras-Mainar A, et al.
Published: (2019)

The concept of: Generic drugs and patented drugs Vs brand name drugs and non-proprietary (generic) name drugs.
by: Karan eThakkar, et al.
Published: (2013)

Gabapentin and Pregabalin in chronic neuropathic pain: cost efficacy evaluation
by: Paolo Marchettini, et al.
Published: (2005)

Impact on healthcare resource utilization of multiple sclerosis in Spain
by: Antoni Sicras-Mainar, et al.
Published: (2017)

Costes y patrón de uso de servicios en pacientes que demandan atención por problemas mentales en asistencia primaria Patterns of health services use and costs in patients with mental disorders in primary care
by: Josep Serrat Tarrés, et al.
Published: (2007)

Comparison of Pharmaceutical Characteristics between Brand-Name Meropenem and Its Generics
by: Ping Yang, et al.
Published: (2021)

Safety of switching from brand-name to generic levetiracetam in patients with epilepsy
by: Bosak M, et al.
Published: (2017)

Impacto de la morbilidad, uso de recursos y costes en el mantenimiento de la remisión de la depresión mayor en España: estudio longitudinal de ámbito poblacional Impact of morbidity, resource use and costs on maintenance of remission of major depression in Spain: a longitudinal study in a population setting
by: Antoni Sicras-Mainar, et al.
Published: (2010)

Cisplatin-induced hyponatremia in malignancy: comparison between brand-name and generic formulation
by: Ochi N, et al.
Published: (2014)

Use of metformin and vildagliptin for treatment of type 2 diabetes in the elderly
by: Sicras-Mainar A, et al.
Published: (2014)

Validación retrospectiva del Johns-Hopkins ACG Case-Mix System en la población Española Validating the Adjusted Clinical Groups [ACG] Case-mix System in a Spanish population setting: a multicenter study
by: Antoni Sicras-Mainar, et al.
Published: (2009)

Treatment profiles and costs of patients with chronic pain in the population setting
by: Sicras Mainar A, et al.
Published: (2012)

Clinical equivalence of generic and brand-name drugs used in cardiology: what do we know?
by: Marina V. Leonova
Published: (2021)

Gabapentin improves neuropathic pain in Minamata disease model rats
by: Masatake Fujimura
Published: (2024)

Generic versus brand-name over-the-counter analgesics: knowledge and attitudes among Swedish pharmacy customers
by: Helle Håkonsen, et al.
Published: (2020)

Cost and clinical consequences of smoking cessation in outpatients after cardiovascular disease: a retrospective cohort study
by: Sicras-Mainar A, et al.
Published: (2013)

Evaluation of Patient Assistance Program Eligibility and Availability for Top 200 Brand Name and Generic Drugs in the United States
by: Chin-Fun Chu, et al.
Published: (2012)

Evaluation of Patient Assistance Program Eligibility and Availability for Top 200 Brand Name and Generic Drugs in the United States
by: Chin-Fun Chu, et al.
Published: (2012)

Can income-based co-payment rates improve disparity? The case of the choice between brand-name and generic drugs
by: Yuki Ito, et al.
Published: (2019)

Public Health Outcomes May Differ After Switching from Brand-Name to Generic Angiotensin II Receptor Blockers
by: Jacinthe Leclerc, et al.
Published: (2020)

Facial Flushing Associated with Anxiety and Improved by Venlafaxine: A Case Report
by: Qiu Y, et al.
Published: (2022)

Investigation of the efficacy of generic and brand-name tiotropium bromide in the management of chronic obstructive pulmonary disease: A randomized comparative trial
by: Yunes Panahi, et al.
Published: (2016)

Use of gabapentin for neuropathic pain therapy: A view from perspective of evidence-based medicine
by: O. I. Butranova, et al.
Published: (2024)

Clinical outcomes of generic versus brand‐name clopidogrel for secondary prevention in patients with acute myocardial infarction: A nationwide cohort study
by: Cze Ci Chan, et al.
Published: (2023)

Generic Drugs or Branded Generics, Which One You Prefer to Prescribe?
by: Manjunath Premanath, et al.
Published: (2024)

Healthcare resources and costs associated with nonvalvular atrial fibrillation in Spain: apixaban versus acenocoumarol
by: Josep Comin Colet, et al.
Published: (2023)

A comprehensive quality control and cost comparison study of branded and generic angiotensin receptor blockers
by: Arvind Kumar Sharma, et al.
Published: (2024)

Costs and healthcare utilisation of patients with heart failure in Spain
by: Carlos Escobar, et al.
Published: (2020)

Clinical validity of a population database definition of remission in patients with major depression
by: Salvatella-Pasant Jordi, et al.
Published: (2010)

Design and evaluation of cost-effective oro-dispersible tablets of venlafaxine hydrochloride by effervescent method
by: Sunita Mahale, et al.
Published: (2024)

Pregabalin versus SSRIs and SNRIs in benzodiazepine-refractory outpatients with generalized anxiety disorder: a post hoc cost-effectiveness analysis in usual medical practice in Spain
by: De Salas-Cansado M, et al.
Published: (2012)

Generic Tacrolimus (Tacrobell®) Shows Comparable Outcomes to Brand-Name Tacrolimus in the Long-Term Period After Adult Deceased Donor Liver Transplantation
by: Kim JM, et al.
Published: (2019)

Molecular basis for the dosing time-dependency of anti-allodynic effects of gabapentin in a mouse model of neuropathic pain
by: Tsuda Makoto, et al.
Published: (2010)

Medida de los pesos relativos del coste de la asistencia como efecto de la aplicación retrospectiva de los adjusted clinical groups en atención primaria Measurement of relative cost weights as an effect of the retrospective application of adjusted clinical groups in primary care
by: Antoni Sicras-Mainar, et al.
Published: (2006)

Costs and healthcare utilisation of patients with chronic kidney disease in Spain
by: Carlos Escobar, et al.
Published: (2021)

Posibilidades de los Grupos Clínicos Ajustados (Ajusted Clinical Groups-ACGs) en el ajuste de riesgos de pago capitativo
by: Antoni Sicras-Mainar, et al.
Published: (2006)

Is There a Potential of Misuse for Venlafaxine and Bupropion?
by: Fabrizio Schifano, et al.
Published: (2018)

Study of mental health outcomes associated with different brands of venlafaxine at the Kumeu medical centre from January 2017 to October 2018
by: William Ferguson, et al.
Published: (2020)